These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Pharmaceuticals: Pharmacy Benefit Managers (PBMs). Seay M; Lee LL Issue Brief Health Policy Track Serv; 2007 Jan; ():1-14. PubMed ID: 17361468 [No Abstract] [Full Text] [Related]
25. Specialty pharmacy management. Interview by Ian Morrison. Stern D Manag Care; 2007 Sep; 16(9 Suppl 9):28-30. PubMed ID: 17977130 [No Abstract] [Full Text] [Related]
26. It's not just the cost of drugs, but the larger drug-use system that needs fixing. Eckel FM N C Med J; 2003; 64(6):296-7. PubMed ID: 14983623 [No Abstract] [Full Text] [Related]
27. Obtaining reimbursement for oncology pharmacy services provided to ambulatory patients. Chong SF; Rospond RM Am J Hosp Pharm; 1993 Oct; 50(10):2057-8. PubMed ID: 8238043 [No Abstract] [Full Text] [Related]
29. Health plans pay less when PBM owns mail-order pharmacy. Manag Care; 2005 Oct; 14(10):68. PubMed ID: 16277196 [No Abstract] [Full Text] [Related]
30. Gastro-oesophageal acid-related disease, co-morbidity and medical care cost. Jayadevappa R; Chhatre S; Weiner M Chronic Illn; 2008 Sep; 4(3):209-18. PubMed ID: 18796510 [TBL] [Abstract][Full Text] [Related]
31. Removing patient access barriers through informatics integration in a clinic-based outpatient pharmacy. Boesken TA; Dalhover A; McKinney KC Am J Health Syst Pharm; 2019 Apr; 76(8):489-492. PubMed ID: 31361868 [No Abstract] [Full Text] [Related]
32. Introducing an ROI model for pharmacy services. Sipkoff M Manag Care; 2006 Mar; 15(3):11-2. PubMed ID: 16604923 [No Abstract] [Full Text] [Related]
33. Organizational and client determinants of cost in outpatient substance abuse treatment. Beaston-Blaakman A; Shepard D; Horgan C; Ritter G J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043 [TBL] [Abstract][Full Text] [Related]
34. [On the future of clinical pharmacy . Gearing of the outpatient and inpatient sector required]. Bertsche T Med Monatsschr Pharm; 2015 Jan; 38(1):22-3. PubMed ID: 26349122 [No Abstract] [Full Text] [Related]
35. Association Between Narrow Pharmacy Networks and Medication Adherence. Polinski JM; Matlin OS; Sullivan C; Gagnon M; Brennan TA; Shrank WH JAMA Intern Med; 2015 Nov; 175(11):1850-3. PubMed ID: 26348504 [No Abstract] [Full Text] [Related]
36. Attention Turns to Specialty Pharmacy. Dross D Benefits Q; 2017; 33(2):12-15. PubMed ID: 29782733 [TBL] [Abstract][Full Text] [Related]
37. Entry of new pharmacies in the deregulated Norwegian pharmaceuticals market--consequences for costs and availability. Rudholm N Health Policy; 2008 Aug; 87(2):258-63. PubMed ID: 18164509 [TBL] [Abstract][Full Text] [Related]
38. The case for a value-based formulary: striving for total lowest net cost. Weart W; Bauman GR Manag Care Interface; 2007 Apr; 20(4):42-7. PubMed ID: 17474330 [TBL] [Abstract][Full Text] [Related]
39. A decade of economic challenges to pharmacy. Paul SH Med Mark Media; 1981 Nov; 16(11):31-2, 34-6. PubMed ID: 10253532 [No Abstract] [Full Text] [Related]
40. PBMs' rebate income threatened by lawsuits and move to generics. Sipkoff M Manag Care; 2008 Mar; 17(3):11-2. PubMed ID: 18447152 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]